We conclude that regimens that more strongly suppress ERα might be useful in targeting endocrine resistant ER+ breast cancer cells, and that drug combinations that target the ERα through multiple mechanisms might be a promising strategy to target ERα in endocrine resistant breast cancer cells. Here, ESR1 is linked to breast carcinoma.